Clinical Trial Update: A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of Daikenchuto (TU-100) for Crohn's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Daikenchuto (TU-100) (Daikenchuto)

Snippet

Sponsor: Tsumura USA | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED